Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03906006 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 in Healthy Subjects
A Phase 1 study, sponsored by Atom Therapeutics Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT03906006 is a Phase 1 study that has completed, run by Atom Therapeutics Co.. The registered enrollment target is 32 participants.
The verdict
NCT03906006, a Phase 1 study, has completed, sponsored by Atom Therapeutics Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of ABP-671 administered orally in healthy volunteers.
Interventions
- OTHER Placebo
- DRUG ABP-671
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2018-10-17 |
| Est. Completion | 2019-06-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03906006
The ClinicalTrials.gov registry entry for NCT03906006 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Atom Therapeutics Co., which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03906006 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03906006 about?
NCT03906006 is a clinical study titled "A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 in Healthy Subjects". The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of ABP-671 administered orally in healthy volunteers.
What is the current status of trial NCT03906006?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2018-10-17. Estimated completion is 2019-06-20.
What interventions are being tested in trial NCT03906006?
The interventions under investigation include: Placebo (OTHER), ABP-671 (DRUG).
Who is sponsoring clinical trial NCT03906006?
This trial is sponsored by Atom Therapeutics Co., which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.